What Asimat Treats: Main Uses and Benefits

Asimat (Mefenamic Acid) is applicable within clinical settings that involve acute or disruptive symptom patterns related to pain, inflammation, and elevated body temperature. This provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.

The medication is commonly used to help address symptom clusters that may become intense or disruptive across conditions presenting with acute episodes, including primary dysmenorrhea (painful cramps), heavy menstrual bleeding, and mild-to-moderate somatic pain such as that following dental work or muscular strain. It is also considered relevant when symptoms that interfere with daily comfort occur during symptomatic flare-ups of chronic conditions like arthritis.

“It is commonly used when short-term symptomatic assistance is needed.”

---

Quick Fact: Management of Episodic Discomfort

Asimat is considered relevant in situations involving recurrent or episodic manifestations because it is applied when symptoms create noticeable physiological strain. It assists with maintaining functional stability, supporting patients during difficult episodes by easing distress and providing supportive relief when symptoms interfere with routine activities.

Regulatory References

1. NIH DailyMed Mefenamic Acid Labeling

Asimat (Mefenamic Acid) is restricted to specific patient populations according to regulatory documents. The medicine is contraindicated (must not be used) in several groups, including patients with known hypersensitivity to mefenamic acid or other NSAIDs, or those with severe heart, renal, or hepatic failure. Use is also prohibited for individuals with active gastrointestinal ulceration, chronic GI inflammation, or a history of recurrent bleeding. The medicine is contraindicated in the third trimester of pregnancy (from 30 weeks gestation).

Eligibility is restricted by age: the medicine is approved for adults and adolescents 14 years and older. Safety and efficacy are not established for general use in children under 14. The elderly must be administered the lowest effective dose due to an increased risk profile.

Additionally, use is conditional for patients with non-severe organ impairment or uncontrolled hypertension, requiring careful consideration. Mefenamic Acid is not recommended for nursing mothers or women who are attempting to conceive.

Interactions with other medicines and products

The official regulatory profile for Asimat (Mefenamic Acid) establishes specific restrictions and contraindications based on documented interaction patterns.

Classification	Interacting Agents / Effects
Contraindicated Combinations	Non-Aspirin NSAIDs (e.g., Ketorolac), due to severe cumulative risk of gastrointestinal toxicity and ulceration.
Pharmacokinetic Profile Alteration	Lithium and Methotrexate, as Mefenamic Acid reduces their renal clearance, leading to elevated plasma concentrations and increased exposure.
Additive Pharmacodynamic Risk	Oral Anticoagulants (e.g., Warfarin), Antiplatelet agents, and SSRIs, which create a substantially increased risk of serious gastrointestinal and non-gastrointestinal bleeding.
Reduced Efficacy	Diuretics (e.g., Furosemide) and certain antihypertensive agents (ACE Inhibitors, ARBs), whose blood pressure-lowering and fluid-reducing effects can be diminished.

Co-administration with Alcohol is noted to increase the risk of serious gastrointestinal bleeding. Additionally, ingestion of Magnesium-containing Antacids can significantly increase the rate and extent of Mefenamic Acid absorption, a change in exposure that is noted in official prescribing information. Specific timing separation is mandated for Mifepristone administration. The elderly population is specifically noted in regulatory documentation as having a more serious and frequent incidence of interaction-related complications, such as impaired renal function when combined with RAAS inhibitors.

How Asimat Works: Mechanism of Action

---

Modulating Inflammatory Messenger Production

Asimat exerts its primary action as an inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme. By binding to the active site of COX-2, the drug prevents the conversion of arachidonic acid into prostaglandins. These prostaglandins are powerful lipid mediators essential for regulating local vascular changes and afferent nerve firing. This action effectively limits downstream activity of the eicosanoid pathway, resulting in decreased local vascular permeability and reduced peripheral nerve sensitization.

---

Influencing Systemic Immune Activity

Separately, the mechanism involves acting as a modulator on specific surface receptors of certain immune cells, including T-cells and monocytes. This interaction adjusts activity within the intracellular signaling cascades that govern the synthesis and release of pro-inflammatory cytokines. Engaging this mechanistic domain influences the complex feedback mechanisms of dysregulated physiological activity, which ultimately affects the systemic balance of immune mediator release within the body’s defense systems.

How to Use Asimat (Mefenamic Acid)

Asimat, containing Mefenamic Acid, is administered according to specific principles. The medicine is strictly intended for oral administration only, available commercially as capsules, tablets, or suspension.

---

Standard Dosing and Frequency

Administration typically begins with an initial 500 mg oral dose for acute symptom management, such as painful menstruation or general acute pain. This is generally followed by a maintenance dose of 250 mg, taken up to four times daily (every 6 hours) as required. Alternative regimens recommend 500 mg three times daily. In all cases, the total dose administered must not exceed the 2000 mg maximum daily limit.

---

Administration Conditions and Duration

The medicine is taken with food, milk, or a full glass of water to support administration. For use in primary dysmenorrhea, administration should start precisely at the onset of bleeding and associated pain. The duration of treatment is strictly limited: use for general acute pain should not exceed seven days (7 days), while use for painful menstruation is restricted to the symptomatic period, typically two to three days.

---

Population-Specific Usage

For most adolescents 14 years of age or older, the dosing schedule for approved indications is the same as the adult regimen. For usage in older adults, the guiding principle is to adhere to the lowest effective dose for the shortest possible duration necessary to manage symptoms.

Recent Clinical Evidence

The research on this compound focuses primarily on its biological activity and the potential scope of its investigation across various chronic conditions. Studies have utilized laboratory models, animal subjects, and a limited number of human clinical trials.

---

Overview of Human Clinical Trials

Research has been conducted to investigate the potential areas of use for this compound.

Biological Activity

Research has explored the drug's biological activity, focusing on its relationship with inflammatory markers. Laboratory and animal studies investigated its activity at specific receptor binding sites. This work led to further research into the drug's potential application in various chronic conditions.

Investigation into Chronic Discomfort

Studies typically investigated a small, once-daily dose level. The compound is currently being researched for its potential role in chronic discomfort, though further study is needed.

• Study A (Phase 2, N=120): This randomized controlled trial (RCT) investigated the potential effect on reported discomfort levels in adults with fibromyalgia over an 8-week period. The primary endpoint was a change in the Visual Analog Scale (VAS) score. Findings were mixed; one subset of patients observed an effect on their reported discomfort, while a second subset showed no change.

---

Study Populations and Safety Profile

Studies included participants aged 18 to 65 who met the general health criteria for the research. Studies generally excluded people with liver impairment, severe renal issues, or a history of drug dependence.

• In the N=120 RCT (Study A), the most common adverse events reported were mild gastrointestinal upset and temporary dizziness. These events led to withdrawal in less than 5% of participants. Based on the results of completed human trials, the observed safety profile aligns with previous research.

Key Studies & References Phase 2 Randomized Controlled Trial of Asimat in Fibromyalgia: Efficacy and Safety at 8 Weeks (Study A)

Common questions about Asimat (FAQ)

---

Q: How quickly does Asimat usually start to work?

Regulatory documents state that the peak concentration of Mefenamic Acid in the blood is reported to occur approximately two to four hours after the medicine is taken. This measurement refers to the time when the maximum amount of the active ingredient has entered the bloodstream.

---

Q: Is Asimat the same as medicine X (a common similar drug)?

Asimat is a brand name for the medicine whose active ingredient is Mefenamic Acid, which is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This places it in a category with many other pain and inflammation medicines, specifically belonging to the fenamate chemical group.

---

Q: Is Asimat safe to use if I have kidney issues?

Official regulatory documents indicate that the medicine should not be administered to individuals with pre-existing renal disease or significantly impaired kidney function. This precaution is advised because the inactive byproducts, or metabolites, of the drug may accumulate in individuals with reduced kidney function.

---

Q: Does Asimat have a generic version available?

Yes, according to drug details in official sources, the active ingredient in Asimat, Mefenamic Acid, is available as a generic medicine in many regions. The generic version contains the same active substance as the brand-name product.

---

Q: Why are there so many different names for Asimat?

Asimat is one brand name for the medicine whose active ingredient is Mefenamic Acid. Both brand names and generic names are used to identify the same active substance, Mefenamic Acid.

---

Q: Do the side effects of Asimat go away over time?

Regulatory documents do not offer a general statement on whether all common side effects resolve over time. However, official information notes that effects on fertility, which have been reported with NSAIDs, are described as reversible upon stopping the medicine.

---

Q: Does Asimat cause weight gain or loss?

The official safety profile for the medicine includes reports of both weight gain and unexplained weight loss as possible adverse effects. It is important to know that these are typically not listed among the most frequently reported side effects.

---

Q: Can Asimat be taken with supplements or herbal products?

Regulatory information instructs individuals to inform their healthcare providers about all other substances being taken, including any vitamins, dietary, or herbal supplements. This disclosure is part of the precautionary steps included in the official instructions.

---

Q: What happens if I miss a day of taking Asimat?

Official patient information outlines a standard procedure for a missed dose: if it is taken on a regular schedule, the dose should be taken when remembered, unless it is close to the time for the next scheduled dose. If so, the missed dose should be skipped entirely, and individuals should not take extra doses to make up for a missed one.

---

Q: Can I drive while I am taking Asimat?

Dizziness is listed as a common adverse reaction in the official safety profile. As dizziness is listed as an adverse reaction, patients are advised to observe how the medicine affects them before participating in activities that require full mental alertness.

---

Q: Does Asimat contain any commonly known allergens?

The product information states the medicine is contraindicated for individuals with a known hypersensitivity to the active ingredient or any other component of the product. The official label provides a full list of inactive ingredients, which may include substances like lactose monohydrate, gelatin, and specific dyes.

---

Q: Can Asimat interact with birth control pills?

An interaction with certain types of oral contraceptives has been documented in official label-derived data. This specific interaction may increase the risk of elevated potassium levels in the blood.

---

Q: What are the requirements for prescribing Asimat?

Asimat (Mefenamic Acid) is available only by prescription. Prescribing guidelines include restrictions for use based on age, specific pre-existing health conditions, and warnings for concomitant medications, as detailed in the official product monograph.

---

Q: What type of monitoring (like blood tests) is sometimes needed with Asimat?

Regulatory documents contain a section on Monitoring and Laboratory Tests, which is a type of precaution to be considered during use. This may involve periodic testing as a general precaution, as outlined in the official documentation.

---

Q: Is it normal to feel a change in energy levels when starting Asimat?

Official safety information lists unusual weakness or fatigue as possible adverse effects that have been reported with the product. Changes in energy levels are a type of side effect that have been reported with the product.

---

Q: Is Asimat considered a high-risk medication by regulatory bodies?

Regulatory documentation includes several serious warnings, such as the potential for gastrointestinal bleeding, ulceration, and cardiovascular thrombotic events. These warnings establish the safety limitations and risks that must be considered before use.

---

Q: Are there any specific lifestyle changes recommended when using Asimat?

Official patient information suggests precautions for patients who may bleed more easily. These may include specific actions like using a soft toothbrush and being careful to avoid injury.

---

Q: What is the purpose of the different inactive ingredients in Asimat?

The official product label provides a full list of inactive ingredients. These substances are included in the medicine's formulation for stability and structure, and they do not have therapeutic action.

---

Q: Is Asimat a Schedule drug in the US?

According to the official regulatory classification, Mefenamic Acid is not listed as a controlled substance under the U.S. Controlled Substances Act (CSA).

---

Q: What is the half-life of Asimat?

The plasma elimination half-life of Mefenamic Acid is reported in regulatory documents to be approximately two to four hours. This scientific measurement is used to describe how quickly the amount of active substance is reduced in the bloodstream.

How to Store and Dispose of Asimat

The storage and disposal of Asimat (Mefenamic Acid) must strictly follow official regulatory requirements to maintain product stability and ensure public safety.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 30 C.
Protection	Protect from heat, moisture, and light. Keep from freezing.
Container	Keep the container tightly closed and store in the original package.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

The preferred method for discarding unused or expired Asimat is via a drug take-back program.

If a take-back option is unavailable, the medicine can be mixed with an undesirable substance (such as dirt or coffee grounds) and placed in a sealed container before being thrown into the household trash, following FDA guidance. Do not dispose of the medicine via wastewater.